You just read:

Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer

News provided by

Novartis Pharmaceuticals Corporation

Dec 06, 2017, 12:15 EST